Panel Spotlight: AI and Omics Technologies

13 Aug

By Candice He, Global Investment Strategist, LSN

Life Science Nation (LSN) has been busy this summer recruiting panelists for its Inaugural 4D Meets AI partnering conference, exploring the impact of Artificial Intelligence (AI) on Drugs, Devices, Diagnostics, and Digital Health (the 4 Ds), while facilitating conversations between early-stage companies and strategic partners.

We are pleased to introduce the AI and Omics Technologies panel, discussing the importance of multi-omics data and technology in understanding, early intervention, and treatment of disease. The use of artificial intelligence (AI) and machine learning (ML) in optimizing this data is essential. Get to know the early-stage CEOs innovating this space, and register for a savings of $200 by this Friday using discount code: AI200. Join the conversation September 17-18.

Lisa Alderson, MBA, CEO & Co-Founder, Genome Medical

Lisa Alderson is the CEO and Co-Founder of Genome Medical, Inc., a leading genomics technology and services company that is transforming the delivery of medicine by enabling access to genomic-based medicine for everyday care. Through its nationwide network of genetic specialists and efficient Genome Care DeliveryTM technology platform, Genome Medical provides health expertise throughout the genomics journey. Prior, Ms. Alderson served as the Chief Commercial Officer and Chief Strategy Officer of Invitae (NYSE: NVTA), a rapidly growing genetic information company. She was also the former CEO and president of CrossLoop Inc., a marketplace for technical services (acquired by Nasdaq: AVG). Prior to that, she was part of the start-up team at Genomic Health Inc. (Nasdaq: GHDX), president of Cinema Circle Inc., (acquired by Nasdaq: GAIA) and the former manager of strategic planning at The Walt Disney Co. Lisa also serves on the board of the Kidney Cancer Association. She has a track record of creating, funding and managing high-growth ventures. Lisa has an MBA with distinction from Harvard Business School and a BA from Colorado State University, where she graduated Summa Cum Laude.

Steve Gardner PhD, CEO, RowAnalytics

Steve has over 25 years’ experience building world-class teams, products and companies including as Global Director of Research Informatics for Astra. He has raised venture funding in the UK, EU and USA to develop and market highly innovative and commercially successful products in the life science, healthcare and food industries. Steve specialises in AI enabled precision medicine, drug discovery, large-scale genomics, semantic data integration and complex data analytics for life science, healthcare and clinical decision support. Steve is an Advisory Council member for Breast Cancer Now and is on the Steering Committee of the UKCRC Tissue Coordination Centre.

Jay Goth, Founder & CEO, Murrieta Genomics; President, SimplSeq

Jay Goth is the CEO of Murrieta Genomics and President of SimplSeq, Inc. He is the former Managing Partner of Forentis Fund, a biotech venture capital firm that was focused on biomarker discover, data analytics and precision medicine. He serves as Executive Director of InSoCal CONNECT, a nonprofit that has structured mentorship and training programs for entrepreneurs, was a Senior Consultant with TriTech SBDC, one of seven technology designated Small Business Development Centers operating under the SBA, and served as an Entrepreneur in Residence at the University of California, Riverside. He holds board positions with several for-profit and non-profit enterprises.

Yatin Mundkur, CEO, Cellworks Group

Committed to the delivery of Precision Medicine for cancer care, Yatin Mundkur leads Cellworks Group in transforming the treatment of cancer through personalized medicine. As CEO of Cellworks, Yatin Mundkur develops company strategy and commercialization of both its Precision Medicine and its Stratified Medicine businesses. Over the last 25 years, Yatin has launched businesses in medical diagnostics, technology and communications, delivering strong returns to investors consistently. As a Partner of Artiman Ventures he focuses on early-stage Technology and Healthcare investments. He is also on the Boards of Prysm, mSupply, Virsec, Xambala, Yantra and zSpace. Prior to joining Artiman Ventures, Yatin Mundkur was Managing Director at TeleSoft Partners, where he led investments in over twenty companies, in the early stage semiconductor and software sectors. Formerly, he held executive and engineering roles in multiple technology companies. He has been awarded fourteen patents, in the areas of computer architectures, digital consumer electronics, semiconductor design, and software. Yatin holds a B.S.E.E. from MSU of Baroda, India, and a M.S.E.E. from the University of Texas at Austin.

Leila Pirhaji, PhD, Founder & CEO, ReviveMed

Dr. Leila Pirhaji is the Founder and CEO of ReviveMed with a PhD in Bioengineering from MIT, where she developed a pioneering artificial intelligence (AI) technology to identify a large number of small molecules or metabolites from blood or tissues of patients rapidly, and translate their data into drug discovery insights. She then founded ReviveMed to bring this technology to the market.  Her innovative work has received several prestigious awards and featured in TV and media outlets. In 2019, Leila gave a TED talk on the medical applications of AI and metabolomics, which has been viewed >1.7 M times. In 2020, Leila was named as a 35 innovator under 35 by the MIT Technology Review.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: